AnaptysBio (NASDAQ:ANAB) Shares Down 3.2% – What’s Next?

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) were down 3.2% during trading on Friday . The stock traded as low as $33.85 and last traded at $33.92. Approximately 23,409 shares were traded during trading, a decline of 93% from the average daily volume of 325,243 shares. The stock had previously closed at $35.03.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on ANAB shares. JPMorgan Chase & Co. lifted their price target on shares of AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Truist Financial lifted their price target on shares of AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a research report on Thursday, August 15th. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price target on shares of AnaptysBio in a research report on Wednesday, August 14th. Finally, Wedbush reaffirmed an “outperform” rating and set a $42.00 price target on shares of AnaptysBio in a research report on Thursday, September 26th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $51.10.

AnaptysBio Stock Down 3.0 %

The company has a market cap of $928.30 million, a PE ratio of -5.53 and a beta of -0.29. The business has a 50-day simple moving average of $35.45 and a 200-day simple moving average of $28.54.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.71) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.82). The business had revenue of $10.97 million during the quarter, compared to analyst estimates of $25.85 million. AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. As a group, equities research analysts predict that AnaptysBio, Inc. will post -6.84 EPS for the current fiscal year.

Insiders Place Their Bets

In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of the business’s stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $38.67, for a total value of $58,005.00. Following the completion of the transaction, the insider now owns 15,398 shares in the company, valued at $595,440.66. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, Director Hollings Renton sold 10,000 shares of the business’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $30.64, for a total transaction of $306,400.00. Following the completion of the transaction, the director now owns 1,950 shares in the company, valued at approximately $59,748. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Paul F. Lizzul sold 1,500 shares of the business’s stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total transaction of $58,005.00. Following the transaction, the insider now owns 15,398 shares of the company’s stock, valued at approximately $595,440.66. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 33,940 shares of company stock worth $1,251,836 over the last 90 days. Corporate insiders own 33.70% of the company’s stock.

Hedge Funds Weigh In On AnaptysBio

Institutional investors and hedge funds have recently modified their holdings of the company. Allspring Global Investments Holdings LLC acquired a new position in shares of AnaptysBio during the first quarter worth $38,000. Headlands Technologies LLC lifted its position in AnaptysBio by 444.8% in the second quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock valued at $89,000 after acquiring an additional 2,900 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in AnaptysBio by 66.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 5,123 shares of the biotechnology company’s stock valued at $115,000 after acquiring an additional 2,051 shares during the last quarter. Duncan Williams Asset Management LLC purchased a new stake in AnaptysBio in the third quarter valued at $282,000. Finally, Virtu Financial LLC purchased a new stake in AnaptysBio in the first quarter valued at $222,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.